Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2021

Open Access 01-12-2021 | Ebola Virus | Review

When MARCH family proteins meet viral infections

Authors: Chunfu Zheng, Yan-Dong Tang

Published in: Virology Journal | Issue 1/2021

Login to get access

Abstract

Membrane-associated RING-CH (MARCH) ubiquitin ligases belong to a RING finger domain E3 ligases family. Recent studies have demonstrated that MARCH proteins play critical roles during various viral infections. MARCH proteins can directly antagonize different steps of the viral life cycle and promote individual viral infection. This mini-review will focus on the latest advances of MARCH family proteins' emerging roles during viral infections.
Literature
1.
Keren-Kaplan T, Attali I, Motamedchaboki K, Davis BA, Tanner N, Reshef Y, et al. Synthetic biology approach to reconstituting the ubiquitylation cascade in bacteria. EMBO J. 2012;31(2):378–90.CrossRef
2.
3.
Bauer J, Bakke O, Morth JP. Overview of the membrane-associated RING-CH (MARCH) E3 ligase family. New Biotechnol. 2017;38(Pt A):7–15.CrossRef
4.
Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology. EMBO Rep. 2006;7(10):1019–22.CrossRef
5.
Kreft SG, Wang L, Hochstrasser M. Membrane topology of the yeast endoplasmic reticulum-localized ubiquitin ligase Doa10 and comparison with its human ortholog TEB4 (MARCH-VI). J Biol Chem. 2006;281(8):4646–53.CrossRef
6.
Nathan JA, Sengupta S, Wood SA, Admon A, Markson G, Sanderson C, et al. The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X. Traffic. 2008;9(7):1130–45.CrossRef
7.
Iyengar PV, Hirota T, Hirose S, Nakamura N. Membrane-associated RING-CH 10 (MARCH10 protein) is a microtubule-associated E3 ubiquitin ligase of the spermatid flagella. J Biol Chem. 2011;286(45):39082–90.CrossRef
8.
Wang X, Herr RA, Hansen T. Viral and cellular MARCH ubiquitin ligases and cancer. Semin Cancer Biol. 2008;18(6):441–50.CrossRef
9.
Zhang Y, Tada T, Ozono S, Yao W, Tanaka M, Yamaoka S, et al. Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection. J Biol Chem. 2019;294(10):3397–405.CrossRef
10.
Zhang Y, Lu J, Liu X. MARCH2 is upregulated in HIV-1 infection and inhibits HIV-1 production through envelope protein translocation or degradation. Virology. 2018;518:293–300.CrossRef
11.
Yoo YS, Park YJ, Lee HS, Oanh NTK, Cho MY, Heo J, et al. Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis. Cell Death Dis. 2019;10(12):938.CrossRef
12.
Goto E, Ishido S, Sato Y, Ohgimoto S, Ohgimoto K, Nagano-Fujii M, et al. c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity. J Biol Chem. 2003;278(17):14657–68.CrossRef
13.
Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K, Früh K. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004;78(3):1109–20.CrossRef
14.
van de Kooij B, Verbrugge I, de Vries E, Gijsen M, Montserrat V, Maas C, et al. Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. J Biol Chem. 2013;288(9):6617–28.CrossRef
15.
Fujita H, Iwabu Y, Tokunaga K, Tanaka Y. Membrane-associated RING-CH (MARCH) 8 mediates the ubiquitination and lysosomal degradation of the transferrin receptor. J Cell Sci. 2013;126(Pt 13):2798–809.CrossRef
16.
Chen R, Li M, Zhang Y, Zhou Q, Shu H-B. The E3 ubiquitin ligase MARCH8 negatively regulates IL-1β-induced NF-κB activation by targeting the IL1RAP coreceptor for ubiquitination and degradation. Proc Natl Acad Sci USA. 2012;109(35):14128–33.CrossRef
17.
Ohmura-Hoshino M, Matsuki Y, Aoki M, Goto E, Mito M, Uematsu M, et al. Inhibition of MHC class II expression and immune responses by c-MIR. J Immunol (Baltimore, Md: 1950). 2006;177(1):341–54.CrossRef
18.
Tze LE, Horikawa K, Domaschenz H, Howard DR, Roots CM, Rigby RJ, et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med. 2011;208(1):149–65.CrossRef
19.
Tada T, Zhang Y, Koyama T, Tobiume M, Tsunetsugu-Yokota Y, Yamaoka S, et al. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med. 2015;21(12):1502–7.CrossRef
20.
Fujita M. Commentary: MARCH8 Inhibits HIV-1 Infection by Reducing Virion Incorporation of Envelope Glycoproteins. Front Microbiol. 2016;7:254.CrossRef
21.
Zhang Y, Tada T, Ozono S, Kishigami S, Fujita H, Tokunaga K. MARCH8 inhibits viral infection by two different mechanisms. eLife. 2020;9:e57763.CrossRef
22.
Yu C, Li S, Zhang X, Khan I, Ahmad I, Zhou Y, et al. MARCH8 inhibits ebola virus glycoprotein, human immunodeficiency virus type 1 envelope glycoprotein, and avian influenza virus H5N1 hemagglutinin maturation. mBio. 2020;11(5):e01882.PubMedPubMedCentral
23.
Kong N, Shan T, Wang H, Jiao Y, Zuo Y, Li L, et al. BST2 suppresses porcine epidemic diarrhea virus replication by targeting and degrading virus nucleocapsid protein with selective autophagy. Autophagy. 2020;16(10):1737–52.CrossRef
24.
Kumar S, Barouch-Bentov R, Xiao F, Schor S, Pu S, Biquand E, et al. MARCH8 ubiquitinates the hepatitis C virus nonstructural 2 protein and mediates viral envelopment. Cell Rep. 2019;26(7):1800–14.CrossRef
25.
Sun Z, Jha HC, Pei Y-G, Robertson ES. Major histocompatibility complex class II HLA-DRα is downregulated by Kaposi’s sarcoma-associated herpesvirus-encoded lytic transactivator RTA and MARCH8. J Virol. 2016;90(18):8047–58.CrossRef
26.
Zheng C. The emerging roles of the MARCH ligases in antiviral innate immunity. Int J Biol Macromol. 2021;171:423–7.CrossRef
Metadata
Title
When MARCH family proteins meet viral infections
Authors
Chunfu Zheng
Yan-Dong Tang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2021
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-021-01520-4

Other articles of this Issue 1/2021

Virology Journal 1/2021 Go to the issue

Research

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

Methodology

Development of a reverse transcription droplet digital PCR (RT-ddPCR) assay for sensitive detection of simian immunodeficiency virus (SIV)

Research

Lineage analysis of human papillomavirus type 39 in cervical samples of Iranian women

Research

Etiology and clinical characteristics of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province, China 2017–2019

Research

Detection of chikungunya virus in the Southern region, Saudi Arabia

Research

STING and cGAS gene expressions were downregulated among HIV-1-infected persons after antiretroviral therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits